Cargando…

AlphaDrug: protein target specific de novo molecular generation

Traditional drug discovery is very laborious, expensive, and time-consuming, due to the huge combinatorial complexity of the discrete molecular search space. Researchers have turned to machine learning methods for help to tackle this difficult problem. However, most existing methods are either virtu...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Hao, Lin, Cheng, Zhao, Dengwei, Tu, Shikui, Xu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802440/
https://www.ncbi.nlm.nih.gov/pubmed/36714828
http://dx.doi.org/10.1093/pnasnexus/pgac227
_version_ 1784861682496962560
author Qian, Hao
Lin, Cheng
Zhao, Dengwei
Tu, Shikui
Xu, Lei
author_facet Qian, Hao
Lin, Cheng
Zhao, Dengwei
Tu, Shikui
Xu, Lei
author_sort Qian, Hao
collection PubMed
description Traditional drug discovery is very laborious, expensive, and time-consuming, due to the huge combinatorial complexity of the discrete molecular search space. Researchers have turned to machine learning methods for help to tackle this difficult problem. However, most existing methods are either virtual screening on the available database of compounds by protein–ligand affinity prediction, or unconditional molecular generation, which does not take into account the information of the protein target. In this paper, we propose a protein target-oriented de novo drug design method, called AlphaDrug. Our method is able to automatically generate molecular drug candidates in an autoregressive way, and the drug candidates can dock into the given target protein well. To fulfill this goal, we devise a modified transformer network for the joint embedding of protein target and the molecule, and a Monte Carlo tree search (MCTS) algorithm for the conditional molecular generation. In the transformer variant, we impose a hierarchy of skip connections from protein encoder to molecule decoder for efficient feature transfer. The transformer variant computes the probabilities of next atoms based on the protein target and the molecule intermediate. We use the probabilities to guide the look-ahead search by MCTS to enhance or correct the next-atom selection. Moreover, MCTS is also guided by a value function implemented by a docking program, such that the paths with many low docking values are seldom chosen. Experiments on diverse protein targets demonstrate the effectiveness of our methods, indicating that AlphaDrug is a potentially promising solution to target-specific de novo drug design.
format Online
Article
Text
id pubmed-9802440
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98024402023-01-26 AlphaDrug: protein target specific de novo molecular generation Qian, Hao Lin, Cheng Zhao, Dengwei Tu, Shikui Xu, Lei PNAS Nexus Physical Sciences and Engineering Traditional drug discovery is very laborious, expensive, and time-consuming, due to the huge combinatorial complexity of the discrete molecular search space. Researchers have turned to machine learning methods for help to tackle this difficult problem. However, most existing methods are either virtual screening on the available database of compounds by protein–ligand affinity prediction, or unconditional molecular generation, which does not take into account the information of the protein target. In this paper, we propose a protein target-oriented de novo drug design method, called AlphaDrug. Our method is able to automatically generate molecular drug candidates in an autoregressive way, and the drug candidates can dock into the given target protein well. To fulfill this goal, we devise a modified transformer network for the joint embedding of protein target and the molecule, and a Monte Carlo tree search (MCTS) algorithm for the conditional molecular generation. In the transformer variant, we impose a hierarchy of skip connections from protein encoder to molecule decoder for efficient feature transfer. The transformer variant computes the probabilities of next atoms based on the protein target and the molecule intermediate. We use the probabilities to guide the look-ahead search by MCTS to enhance or correct the next-atom selection. Moreover, MCTS is also guided by a value function implemented by a docking program, such that the paths with many low docking values are seldom chosen. Experiments on diverse protein targets demonstrate the effectiveness of our methods, indicating that AlphaDrug is a potentially promising solution to target-specific de novo drug design. Oxford University Press 2022-10-07 /pmc/articles/PMC9802440/ /pubmed/36714828 http://dx.doi.org/10.1093/pnasnexus/pgac227 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of National Academy of Sciences. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Physical Sciences and Engineering
Qian, Hao
Lin, Cheng
Zhao, Dengwei
Tu, Shikui
Xu, Lei
AlphaDrug: protein target specific de novo molecular generation
title AlphaDrug: protein target specific de novo molecular generation
title_full AlphaDrug: protein target specific de novo molecular generation
title_fullStr AlphaDrug: protein target specific de novo molecular generation
title_full_unstemmed AlphaDrug: protein target specific de novo molecular generation
title_short AlphaDrug: protein target specific de novo molecular generation
title_sort alphadrug: protein target specific de novo molecular generation
topic Physical Sciences and Engineering
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802440/
https://www.ncbi.nlm.nih.gov/pubmed/36714828
http://dx.doi.org/10.1093/pnasnexus/pgac227
work_keys_str_mv AT qianhao alphadrugproteintargetspecificdenovomoleculargeneration
AT lincheng alphadrugproteintargetspecificdenovomoleculargeneration
AT zhaodengwei alphadrugproteintargetspecificdenovomoleculargeneration
AT tushikui alphadrugproteintargetspecificdenovomoleculargeneration
AT xulei alphadrugproteintargetspecificdenovomoleculargeneration